Markus Weiler - Publications


33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Pham M, Oikonomou D, Hornung B, Weiler M, Heiland S, Bäumer P, Kollmer J, Nawroth PP, Bendszus M. MR neurography detects diabetic neuropathy early and with proximal predominance. Annals of Neurology. PMID 26381658 DOI: 10.1002/ana.24524  0.64
2015 Broggini T, Wüstner M, Harms C, Stange L, Blaes J, Thomé C, Harms U, Mueller S, Weiler M, Wick W, Vajkoczy P, Czabanka M. NDRG1 overexpressing gliomas are characterized by reduced tumor vascularization and resistance to antiangiogenic treatment. Cancer Letters. PMID 26297987 DOI: 10.1016/j.canlet.2015.06.026  0.64
2015 Heckel A, Weiler M, Xia A, Ruetters M, Pham M, Bendszus M, Heiland S, Baeumer P. Peripheral Nerve Diffusion Tensor Imaging: Assessment of Axon and Myelin Sheath Integrity. Plos One. 10: e0130833. PMID 26114630 DOI: 10.1371/journal.pone.0130833  0.64
2015 Bäumer P, Weiler M, Bendszus M, Pham M. Somatotopic fascicular organization of the human sciatic nerve demonstrated by MR neurography. Neurology. 84: 1782-7. PMID 25841030 DOI: 10.1212/WNL.0000000000001526  0.64
2015 Kessler T, Sahm F, Blaes J, Osswald M, Rübmann P, Milford D, Urban S, Jestaedt L, Heiland S, Bendszus M, Hertenstein A, Pfenning PN, Ruiz de Almodóvar C, Wick A, Winkler F, ... ... Weiler M, et al. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. Oncotarget. PMID 25682871 DOI: 10.18632/oncotarget.2910  0.64
2015 Schwarz D, Weiler M, Pham M, Heiland S, Bendszus M, Bäumer P. Diagnostic signs of motor neuropathy in MR neurography: nerve lesions and muscle denervation. European Radiology. 25: 1497-503. PMID 25433411 DOI: 10.1007/s00330-014-3498-x  0.64
2014 Lemke D, Weiler M, Blaes J, Wiestler B, Jestaedt L, Klein AC, Löw S, Eisele G, Radlwimmer B, Capper D, Schmieder K, Mittelbronn M, Combs SE, Bendszus M, Weller M, et al. Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity? Journal of Neurochemistry. PMID 24976529 DOI: 10.1111/Jnc.12802  0.64
2014 Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M, Reifenberger G. MGMT testing--the challenges for biomarker-based glioma treatment. Nature Reviews. Neurology. 10: 372-85. PMID 24912512 DOI: 10.1038/Nrneurol.2014.100  0.64
2014 Bäumer P, Pham M, Ruetters M, Heiland S, Heckel A, Radbruch A, Bendszus M, Weiler M. Peripheral neuropathy: detection with diffusion-tensor imaging. Radiology. 273: 185-93. PMID 24844471 DOI: 10.1148/radiol.14132837  0.64
2014 Zhu Z, Khan MA, Weiler M, Blaes J, Jestaedt L, Geibert M, Zou P, Gronych J, Bernhardt O, Korshunov A, Bugner V, Lichter P, Radlwimmer B, Heiland S, Bendszus M, et al. Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. Cell Stem Cell. 15: 185-98. PMID 24835569 DOI: 10.1016/j.stem.2014.04.007  0.64
2014 Pham M, Bäumer P, Meinck HM, Schiefer J, Weiler M, Bendszus M, Kele H. Anterior interosseous nerve syndrome: fascicular motor lesions of median nerve trunk. Neurology. 82: 598-606. PMID 24415574 DOI: 10.1212/WNL.0000000000000128  0.64
2014 Blaes J, Weiler M, Sahm F, Hentschel B, Osswald M, Czabanka M, Thomé CM, Schliesser MG, Pusch S, Luger S, Winkler F, Radbruch A, Jugold M, Simon M, Steinbach JP, et al. NDRG1 prognosticates the natural course of disease in WHO grade II glioma. Journal of Neuro-Oncology. 117: 25-32. PMID 24395351 DOI: 10.1007/s11060-013-1357-2  0.64
2014 Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G, Eichwald V, Jugold M, Hodecker S, Osswald M, Meisner C, Hielscher T, Rübmann P, et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proceedings of the National Academy of Sciences of the United States of America. 111: 409-14. PMID 24367102 DOI: 10.1073/Pnas.1314469111  0.64
2013 Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology. 81: 1515-22. PMID 24068788 DOI: 10.1212/Wnl.0B013E3182A95680  0.64
2013 Radbruch A, Wiestler B, Kramp L, Lutz K, Bäumer P, Weiler M, Roethke M, Sahm F, Schlemmer HP, Wick W, Heiland S, Bendszus M. Differentiation of glioblastoma and primary CNS lymphomas using susceptibility weighted imaging. European Journal of Radiology. 82: 552-6. PMID 23238364 DOI: 10.1016/j.ejrad.2012.11.002  0.64
2013 Weiler M, Pfenning PN, Thiepold AL, Blaes J, Jestaedt L, Gronych J, Dittmann LM, Berger B, Jugold M, Kosch M, Combs SE, von Deimling A, Weller M, Bendszus M, Platten M, et al. Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment. Oncogene. 32: 1099-109. PMID 22562250 DOI: 10.1038/onc.2012.137  0.64
2012 Bäumer P, Weiler M, Ruetters M, Staub F, Dombert T, Heiland S, Bendszus M, Pham M. MR neurography in ulnar neuropathy as surrogate parameter for the presence of disseminated neuropathy. Plos One. 7: e49742. PMID 23166762 DOI: 10.1371/journal.pone.0049742  0.64
2012 Weiler M, Wick W. Molecular predictors of outcome in low-grade glioma. Current Opinion in Neurology. 25: 767-73. PMID 23160425 DOI: 10.1097/WCO.0b013e32835a0217  0.64
2012 Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, Wick W, Weiler M. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. Plos One. 7: e33449. PMID 22428052 DOI: 10.1371/Journal.Pone.0033449  0.64
2012 Jestaedt L, Lemke D, Weiler M, Pfenning PN, Heiland S, Wick W, Bendszus M. Gadofluorine M enhanced MRI in experimental glioma: superior and persistent intracellular tumor enhancement compared with conventional MRI. Journal of Magnetic Resonance Imaging : Jmri. 35: 551-60. PMID 22045630 DOI: 10.1002/jmri.22869  0.64
2011 Wick W, Blaes J, Weiler M. mTORC 2:1 for chemotherapy sensitization in glioblastoma. Cancer Discovery. 1: 475-6. PMID 22586651 DOI: 10.1158/2159-8290.CD-11-0264  0.64
2011 Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro-Oncology. 13: 566-79. PMID 21636705 DOI: 10.1093/neuonc/nor039  0.64
2011 Wick W, Wick A, Weiler M, Weller M. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. Current Neurology and Neuroscience Reports. 11: 305-12. PMID 21279815 DOI: 10.1007/s11910-011-0184-0  0.64
2010 Berger B, Capper D, Lemke D, Pfenning PN, Platten M, Weller M, von Deimling A, Wick W, Weiler M. Defective p53 antiangiogenic signaling in glioblastoma. Neuro-Oncology. 12: 894-907. PMID 20504876 DOI: 10.1093/neuonc/noq051  0.64
2010 Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bähr O, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. International Journal of Radiation Oncology, Biology, Physics. 77: 670-6. PMID 19836157 DOI: 10.1016/j.ijrobp.2009.05.031  0.64
2008 Rieger J, Lemke D, Maurer G, Weiler M, Frank B, Tabatabai G, Weller M, Wick W. Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. Journal of Neurochemistry. 106: 2436-48. PMID 18662322 DOI: 10.1111/j.1471-4159.2008.05586.x  0.64
2006 Weiler M, Bähr O, Hohlweg U, Naumann U, Rieger J, Huang H, Tabatabai G, Krell HW, Ohgaki H, Weller M, Wick W. BCL-xL: time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells. Cell Death and Differentiation. 13: 1156-69. PMID 16254573 DOI: 10.1038/sj.cdd.4401786  0.64
2005 Uhl M, Weiler M, Wick W, Jacobs AH, Weller M, Herrlinger U. Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. Biochemical and Biophysical Research Communications. 328: 125-9. PMID 15670759 DOI: 10.1016/j.bbrc.2004.12.164  0.64
2004 Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Research. 64: 7954-61. PMID 15520202 DOI: 10.1158/0008-5472.Can-04-1013  0.64
2004 Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Research. 64: 7596-603. PMID 15492287 DOI: 10.1158/0008-5472.CAN-04-1627  0.64
2001 de Silva R, Weiler M, Morris HR, Martin ER, Wood NW, Lees AJ. Strong association of a novel Tau promoter haplotype in progressive supranuclear palsy. Neuroscience Letters. 311: 145-8. PMID 11578815 DOI: 10.1016/S0304-3940(01)02109-7  0.64
2000 Holtrich U, Wolf G, Yuan J, Bereiter-Hahn J, Karn T, Weiler M, Kauselmann G, Rehli M, Andreesen R, Kaufmann M, Kuhl D, Strebhardt K. Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages. Oncogene. 19: 4832-9. PMID 11039900 DOI: 10.1038/Sj.Onc.1203845  0.64
1999 Kauselmann G, Weiler M, Wulff P, Jessberger S, Konietzko U, Scafidi J, Staubli U, Bereiter-Hahn J, Strebhardt K, Kuhl D. The polo-like protein kinases Fnk and Snk associate with a Ca(2+)- and integrin-binding protein and are regulated dynamically with synaptic plasticity. The Embo Journal. 18: 5528-39. PMID 10523297 DOI: 10.1093/Emboj/18.20.5528  0.64
Show low-probability matches.